Federal Circuit Affirms District Court Decision Holding Asserted Software Claims Invalid as Directed to Patent Ineligible Subject Matter

Oct 28, 2016

Reading Time : 1 min

The Federal Circuit affirmed the district court’s decision and found that the claims were directed to a patent-ineligible abstract idea: the concept of analyzing records of human activity to detect suspicious behavior.  The court agreed that the claimed method is nothing more than a combination of several abstract ideas previously found ineligible under § 101, including collecting information, analyzing information and presenting the results of an abstract process.

The court contrasted the claims of the ’500 patent with those at issue in McRO, Inc. v. Bandai Namco Games America, Inc. In McRO, the court found McRO’s claims patent-eligible because they were directed to a specific asserted improvement in computer animation that used rules to accurately synchronize animated lips for on screen characters. This was previously done by animators; thus, the rules were critical to the implementation of the process on a computer. In contrast, the claims in the ’500 patent did not use rules to improve an existing technological process, but rather merely implemented an old practice in a new environment

Turning to step two of the patent-eligibility inquiry, the court found that the claims fail to add something more or transform the claimed abstract idea of collecting information and analyzing into a patent-eligible application of the abstract idea. The ’500 patent claims merely use generic computer elements such as microprocessors and user interfaces, which are not enough to transform an otherwise abstract idea into patent-eligible subject matter. Moreover, the claims do not propose a solution or overcome a problem specifically arising in the realm of computer technology.

The court also rejected FairWarning’s argument that the ’500 patent does not pre-empt the field of Health Insurance Portability and Accountability Act (HIPAA) regulation compliance. The court held that the absence of complete field pre-emption does not demonstrate patent eligibility, and the fact that the ’500 patent’s claims might not pre-empt the entire field of HIPAA compliance does not make them any less abstract.

FairWarning IP, LLC v. Iatrict Systems, Inc., Case No. 2015-1985 (Fed. Cir. Oct. 11, 2016).

Share This Insight

Previous Entries

IP Newsflash

March 24, 2025

The Federal Circuit affirmed a Patent Trial and Appeal Board (PTAB) final written decision holding that the prior art exception of AIA Section 102(b)(2)(B) does not apply to a prior sale by an inventor when the sale is conducted in private. According to the Federal Circuit, a sale must disclose the relevant aspects of the invention to the public to qualify for the prior art exception of Section 102(b)(2)(B).

...

Read More

IP Newsflash

March 21, 2025

Under the Lanham Act, a plaintiff who prevails on a trademark infringement claim may be entitled to recover the “defendant’s profits” as damages. The Supreme Court in Dewberry Group, Inc. v. Dewberry Engineers Inc. unanimously construed “defendant’s profits” in 35 USC § 1117(a) to mean that only the named defendant’s profits can be awarded, not the profits of other related corporate entities. The Court, however, left open the possibility that other language in § 1117(a) may allow for damages linked to the profits of related entities, if properly raised and supported.

...

Read More

IP Newsflash

March 13, 2025

In a series of rulings on a motion in limine, the District of Delaware recently distinguished between what qualifies as being incorporated by reference and what does not for the purposes of an anticipation defense. In short, a parenthetical citation was held to be insufficient, while three passages discussing a cited reference met the test.

...

Read More

IP Newsflash

March 4, 2025

On February 28, 2025, the USPTO announced that it was rescinding former Director Vidal’s 2022 memorandum on discretionary denials by the Patent Trial and Appeal Board. The 2022 memorandum effectively narrowed the application of discretionary denials in cases with parallel district court litigation by specifying instances where discretionary denial could not be issued. With the withdrawal of the memorandum, individual PTAB panels will regain flexibility in weighing discretionary denials. While the long-term effect of that increased flexibility is not yet known, the immediate effect is likely to be a shift towards the discretionary analysis applied by PTAB panels before the issuance of the memorandum.

...

Read More

IP Newsflash

March 3, 2025

A District of Delaware judge recently granted a defendant’s motion to include a patent prosecution bar in its proposed protective order after determining that litigation counsel’s ability to practice before the Patent Office—without ever having represented the plaintiffs at the Patent Office in the past—weighed heavily in favor of the bar.

...

Read More

IP Newsflash

February 12, 2025

The Federal Circuit recently reversed a district court decision that found a patent that did not describe after-arising technology failed to satisfy the written description requirement. In so doing, the Federal Circuit explained that written description and enablement are evaluated based on the subject matter that is claimed, not the products that practice those claims. As a result, the patentee was not required to describe unclaimed, later-discovered features of the accused products despite the broad language in the claims that undisputedly covered the products.

...

Read More

IP Newsflash

January 24, 2025

The District of Delaware recently rejected a patentee’s argument that non-production of an opinion letter from counsel, combined with knowledge of the patent, warranted a finding that defendant induced infringement.

...

Read More

IP Newsflash

January 17, 2025

The District of Delaware recently denied a motion to dismiss a patent infringement complaint involving gene editing technology that sought relief under the Safe Harbor Provision of the Hatch-Waxman Act. Specifically, the court found the patentee’s complaint sufficiently alleged at least some uses of the claimed technology that, when taken as true, were not solely uses of a “patented invention” that were “reasonably related” to an FDA submission.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.